Ironwood Pharmaceuticals | IRWD - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
Agios Pharmaceuticals USD 1.3B 88.48M 2025-12
Akebia Therapeutics USD 376.56M 12.41M 2025-12
Almirall EUR 2.34B 29.21M 2025-12
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
Amarin USD 670.78M 10.96M 2025-12
Ardelyx USD 501.6M 15.43M 2025-12
Astellas Pharma JPY 3.6T 153.62B 2025-12
AstraZeneca USD 114.07B 382M 2025-12
Charles River Laboratories USD 7.14B 378.39M 2025-12
Coherus Biosciences USD 258.34M 258.18M 2025-12
Emergent BioSolutions USD 1.82B 69.9M 2023-12
Esperion Therapeutics USD 465.89M 101.87M 2025-12
Halozyme Therapeutics USD 2.53B 304.09M 2025-12
Incyte USD 6.96B 627.62M 2025-12
Ironwood Pharmaceuticals USD 396.06M 53.12M 2025-09
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
Lexicon Pharmaceuticals USD 184.99M 20.94M 2025-12
MacroGenics USD 256.85M 13.92M 2025-12
Moderna USD 12.34B 203M 2025-12
Myriad Genetics USD 706.6M 21.5M 2025-12
Pacira USD 1.26B 32.66M 2025-12
PTC Therapeutics USD 2.9B 255.07M 2025-12
Puma Biotechnology USD 202.86M 7.95M 2025-09
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Takeda JPY 15.41T 938.47B 2025-12
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12